Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1016/J.SCHRES.2021.05.018 | ||||
| Año | 2022 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Despite years of research, the mechanisms governing the onset, relapse, symptomatology, and treatment of schizophrenia (SZ) remain elusive. The lack of appropriate analytic tools to deal with the heterogeneity and complexity of SZ may be one of the reasons behind this situation. Deep learning, a subfield of artificial intelligence (AI) inspired by the nervous system, has recently provided an accessible way of modeling and analyzing complex, high-dimensional, nonlinear systems. The unprecedented accuracy of deep learning algorithms in classification and prediction tasks has revolutionized a wide range of scientific fields and is rapidly permeating SZ research. Deep learning has the potential of becoming a valuable aid for clinicians in the prediction, diagnosis, and treatment of SZ, especially in combination with principles from Bayesian statistics. Furthermore, deep learning could become a powerful tool for uncovering the mechanisms underlying SZ thanks to a growing number of techniques designed for improving model interpretability and causal reasoning. The purpose of this article is to introduce SZ researchers to the field of deep learning and review its latest applications in SZ research. In general, existing studies have yielded impressive results in classification and outcome prediction tasks. However, methodological concerns related to the assessment of model performance in several studies, the widespread use of small training datasets, and the little clinical value of some models suggest that some of these results should be taken with caution.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Cortes-Briones, Jose A. | Hombre |
VA Connecticut Hlthcare Syst - Estados Unidos
Connecticut Mental Hlth Ctr - Estados Unidos YALE UNIV - Estados Unidos Yale School of Medicine - Estados Unidos VA Connecticut Healthcare System - Estados Unidos Connecticut Mental Health Center - Estados Unidos |
| 2 | Tapia-Rivas, Nicolas I. | Hombre |
Universidad de Chile - Chile
|
| 3 | D'Souza, Deepak Cyril | Hombre |
VA Connecticut Hlthcare Syst - Estados Unidos
Connecticut Mental Hlth Ctr - Estados Unidos YALE UNIV - Estados Unidos Yale School of Medicine - Estados Unidos VA Connecticut Healthcare System - Estados Unidos Connecticut Mental Health Center - Estados Unidos |
| 4 | ESTEVEZ-VALENCIA, PABLO ANTONIO | Hombre |
Universidad de Chile - Chile
|
| Fuente |
|---|
| Fondo Nacional de Desarrollo Científico y Tecnológico |
| National Institutes of Health |
| Yale University |
| Brain and Behavior Research Foundation |
| Wallace Foundation |
| Takeda |
| Roche |
| Takeda Pharmaceuticals U.S.A. |
| ANID-Chile |
| CH TAC |
| Heffter Research Institute |
| Agradecimiento |
|---|
| JAC reports receiving funding administered through Yale University from the National Institutes of Health, and the Brain and Behavior Research Foundation. DCD reports receiving funding administered through Yale University from the National Institutes of Health, the Brain and Behavior Research Foundation, the Wallace Foundation, CH TAC, LLC, Takeda, Roche, and the Heffter Research Institute. PE reports receiving funding from ANID-Chile. |
| JAC reports receiving funding administered through Yale University from the National Institutes of Health , and the Brain and Behavior Research Foundation . DCD reports receiving funding administered through Yale University from the National Institutes of Health , the Brain and Behavior Research Foundation , the Wallace Foundation , CH TAC, LLC , Takeda , Roche , and the Heffter Research Institute . PE reports receiving funding from ANID-Chile . |
| JAC reports receiving funding administered through Yale University from the National Institutes of Health , and the Brain and Behavior Research Foundation . DCD reports receiving funding administered through Yale University from the National Institutes of Health , the Brain and Behavior Research Foundation , the Wallace Foundation , CH TAC, LLC , Takeda , Roche , and the Heffter Research Institute . PE reports receiving funding from ANID-Chile . |